Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors

Cancer Research

Volumn 59, Issue 22, 1999, Pages 5745-5750

  Toretsky, Jeffrey A ^a   Thakar, Manjusha ^a   Eskenazi, Allen E ^a   Frantz, Christopher N ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN C; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EWING SARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL TRANSFORMATION, NEOPLASTIC; DNA FRAGMENTATION; DOXORUBICIN; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IN SITU NICK-END LABELING; INSULIN-LIKE GROWTH FACTOR I; NEOPLASM PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 0033571748     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Horowitz, M. E., Malawer, M. M., DeLaney, T. F., and Tsokos, M. G. Ewing's sarcoma family of tumors. Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: P. Pizzo and D. Poplack (eds.), Principles and Practice of Pediatric Oncology, pp. 795-821. Philadelphia: J. B. Lippincott, 1993.
2. Wexler, L. H., DeLaney, T. F., Tsokos, M., Avila, N., Steinberg, S. M., Weaver-McClure, L., Jacobson, J., Jarosinski, P., Hijazi, Y. M., Balis, F. M., and Horowitz, M. E. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer (Phila.), 78: 901-911, 1996.
3. Miser, J. S., Krailo, M., Meyers, P., Rausen, A., Link, M., Tarbell, N., Fryer, C., Pritchard, D., Gebhardt, M., Dickman, P., Pearlman, E., Moore, S., Vietti, T., and Grier, H. Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: failure of new regimens to improve outcome. Proc. Annu. Meet. Am. Soc. Clin. Oncol., Vol. 15, A1472, 1996.
4. Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., deJong, P., Rouleau, G., Aurias, A., and Thomas, G. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature (Lond.), 359: 162-165, 1992.
5. Dunn, T., Praissman, L., Hagag, N., and Viola, M. V. ERG gene is translocated in an Ewing's sarcoma cell line. Cancer Genet. Cytogenet., 76: 19-22, 1994.
6. Sorensen, P. H., Lessnick, S. L., Lopez, T. D., Liu, X. F., Triche, T. J., and Denny, C. T. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet., 6: 146-151, 1994.
7. May, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., Hromas, R., and Denny, C. T. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol., 13: 7393-7398, 1993.
8. Toretsky, J. A., Kalebic, T., Blakesley, V., LeRoith, D., and Helman, L. J. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J. Biol. Chem., 272: 30822-30827, 1997.
9. Scotlandi, K., Benini, S., Sarti, M., Serra, M., Lollini, P. L., Maurici, D., Picci, P., Manara, M. C., and Baldini, N. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res., 56: 4570-4574, 1996.
10. Yee, D., Favoni, R. E., Lebovic, G. S., Lombana, F., Powell, D. R., Reynolds, C. P., and Rosen, N. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J. Clin. Investig., 86: 1806-1814, 1990.
11. Werner, H., and LeRoith, D. The role of the insulin-like growth factor system in human cancer. Adv. Cancer Res., 68: 183-223, 1996.
12. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Washington DC), 279: 563-566, 1998.
13. Hankinson, S. E., Willet, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-1396, 1998.
14. Kulik, G., Klippel, A., and Weber, M. J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17: 1595-1606, 1997.
15. Parrizas, M., Saltiel, A. R., and LeRoith, D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem., 272: 154-161, 1997.
16. Datta, S., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
17. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Washington DC), 278: 687-689, 1997.
18. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., and Hawkins, P. T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphale-dependent activation of protein kinase B [see comments]. Science (Washington DC), 279; 710-714, 1998.
19. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., and Hawkins, P. T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B [see comments]. Science (Washington DC), 277: 567-570, 1997.
20. Kalebic, T., Tsokos, M., and Helman, L. J. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res., 54: 5531-5534, 1994.
21. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt [see comments]. Science (Washington DC), 275: 661-665, 1997.
22. Datta, K., Bellacosa, A., Chan, T. O., and Tsichlis, P. N. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem., 271: 30835-30839, 1996.
23. Toretsky, J. A., Connell, Y., Neckers, L., and Bhat, N. K. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J. Neurooncol., 31: 9-16, 1997.
24. Murga, C., Laguinge, L., Wetzker, R., Cuadrado, A., and Gutkind, J. S. Activation of Akt/protein kinase B by G protein-coupled receptors. A role for α and βγ subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase γ. J. Biol. Chem., 273: 19080-19085, 1998.
25. Anilkumar, T. V., Sarraf, C. E., Hunt, T., and Alison, M. R. The nature of cytotoxic drug-induced cell death in murine intestinal crypts. Br. J. Cancer, 65: 552-558, 1992.
26. Ahmed, N. N., Grimes, H. L., Bellacosa, A., Chan, T. O., and Tsichlis, P. N. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc. Natl. Acad. Sci. USA, 94: 3627-3632, 1997.
27. Kulik, G., and Weber, M. J. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol. Cell. Biol., 18: 6711-6718, 1998.
28. Yu, J. C., Gutkind, J. S., Mahadevan, D., Li, W., Meyers, K. A., Pierce, J. H., and Heidaran, M. A. Biological function of PDGF-induced PI-3 kinase activity: its role in α PDGF receptor-mediated mitogenic signaling. J. Cell Biol., 127: 479-487, 1994.
29. Franke, T. F., Kaplan, D. R., Cantley, L. C., Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. PI3K: downstream AKTion blocks apoptosis. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Cell, 88: 435-437, 1997.
30. van Valen, F., Winkelmann, W., and Jurgens, H. Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J. Cancer Res. Clin. Oncol., 118: 269-275, 1992.
31. Matthews, C. C., and Feldman, E. L. Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J. Cell. Physiol., 166: 323-331, 1996.
32. Dore, S., Kar, S., and Quirion, R. Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci. USA, 94: 4772-4777, 1997.
33. Giuliano, M., Lauricella, M., Vassallo, E., Carabillo, M., Vento, R., and Tesoriere, G. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors. Investig. Ophthalmol. Visual Sci., 39: 1300-1311, 1998.
34. Downward, I. Ras signalling and apoptosis. Curr. Opin. Genet. Dev., 8: 49-54, 1998.
35. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science (Washington DC), 282: 1318-1321, 1998.
36. Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell, 87: 619-628, 1996.
37. Okubo, Y., Blakesley, V. A., Stannard, B., Gutkind, S., and Le Roith, D. Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem., 273: 25961-25966, 1998.